Comparative efficacy of in vitro and in vivo metabolized aspirin in the DeBakey ventricular assist device

Journal of Thrombosis and Thrombolysis

Volumn 37, Issue 4, 2014, Pages 499-506

  Sheriff, Jawaad ^a   Girdhar, Gaurav ^a   Chiu, Wei Che ^a   Jesty, Jolyon ^a   Slepian, Marvin J ^a,b   Bluestein, Danny ^a  

^a St Francis Hospital The Heart Center   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Aspirin; Platelets; Thrombin; Ventricular assist devices

Indexed keywords

ACETYLSALICYLIC ACID; ASCRIPTIN; BLOOD CLOTTING FACTOR 10A; THROMBIN; ANTITHROMBOCYTIC AGENT;

ADULT; ARTICLE; BLOOD CLOTTING; BLOOD DONOR; CONTROLLED STUDY; DRUG EFFICACY; DRUG METABOLISM; ENZYME ASSAY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; NORMAL HUMAN; PRIORITY JOURNAL; SHEAR STRESS; THROMBOCYTE; THROMBOCYTE ACTIVATION; VENTRICULAR ASSIST DEVICE; BLOOD; COMPARATIVE STUDY; DRUG EFFECTS; FEMALE; HEART ASSIST DEVICE; MALE; METABOLISM; PATHOLOGY; THROMBOSIS;

ASPIRIN; BLOOD DONORS; BLOOD PLATELETS; FEMALE; HEART-ASSIST DEVICES; HUMANS; MALE; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; THROMBOSIS;

EID: 84899965406     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-0997-6     Document Type: Article

References (53)

1. Christiansen S, Klocke A, Autschbach R (2008) Past, present, and future of long-term mechanical cardiac support in adults. J Card Surg 23(6):664-676. doi:10.1111/j.1540-8191.2008.00696.x
2. Bellumkonda L, Bonde P (2012) Ventricular assist device therapy for heart failure-past, present, and future. Int Anesthesiol Clin 50(3):123-145. doi:10.1097/AIA.0b013e31826233a9
3. Eckman PM, John R (2012) Bleeding and thrombosis in patients with continuous-flow ventricular assist devices. Circulation 125(24):3038-3047. doi:10.1161/CIRCULATIONAHA.111.040246
4. Ensor CR, Paciullo CA, Cahoon WD Jr, Nolan PE Jr (2011) Pharmacotherapy for mechanical circulatory support: a comprehensive review. Ann Pharmacother 45(1):60-77. doi:10.1345/aph.1P459
5. Harrison P, Frelinger AL 3rd, Furman MI, Michelson AD (2007) Measuring antiplatelet drug effects in the laboratory. Thromb Res 120(3):323-336. doi:10.1016/j.thromres.2006.11.012 (Pubitemid 46879909)
6. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S (2008) Assessing the current role of platelet function testing. Clin Cardiol 31(3 Suppl 1):I10-I16. doi:10.1002/clc.20361 (Pubitemid 351442476)
7. Wever-Pinzon O, Stehlik J, Kfoury AG, Terrovitis JV, Diakos NA, Charitos C, Li DY, Drakos SG (2012) Ventricular assist devices: pharmacological aspects of a mechanical therapy. Pharmacol Ther 134(2):189-199. doi:10.1016/j. pharmthera.2012.01.003
8. Majeed F, Kop WJ, Poston RS, Kallam S, Mehra MR (2009) Prospective, observational study of antiplatelet and coagulation biomarkers as predictors of thromboembolic events after implantation of ventricular assist devices. Nat Clin Pract Cardiovasc Med 6(2):147-157. doi:10.1038/ncpcardio1441
9. Slaughter MS, Sobieski MA 2nd, Graham JD, Pappas PS, Tatooles AJ, Koenig SC (2011) Platelet activation in heart failure patients supported by the HeartMate II ventricular assist device. Int J Artif Organs 34(6):461-468. doi:10.5301/IJAO.2011.8459
10. Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA (1995) Description of an in vitro platelet function analyzer-PFA-100. Semin Thromb Hemost 21(Suppl 2):106-112
11. Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ (1998) PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 24(2):195-202. doi:10.1055/s-2007- 995840 (Pubitemid 28180831)
12. Varon D, Dardik R, Shenkman B, Kotev-Emeth S, Farzame N, Tamarin I, Savion N (1997) A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions. Thromb Res 85(4):283-294 (Pubitemid 27143804)
13. Varon D, Lashevski I, Brenner B, Beyar R, Lanir N, Tamarin I, Savion N (1998) Cone and plate(let) analyzer: monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions. Am Heart J 135(5 Pt 2 Su):S187-S193
14. Alstrom U, Granath F, Oldgren J, Stahle E, Tyden H, Siegbahn A (2009) Platelet inhibition assessed with VerifyNow, flow cytometry and PlateletMapping in patients undergoing heart surgery. Thromb Res 124(5):572-577. doi:10.1016/j.thromres.2009.06.024
15. Michelson AD, Frelinger AL 3rd, Furman MI (2006) Current options in platelet function testing. Am J Cardiol 98(10A):4N-10N. doi:10.1016/j.amjcard. 2006.09.008
16. Michelson AD (2009) Methods for the measurement of platelet function. Am J Cardiol 103(3 Suppl):20A-26A. doi:10.1016/j.amjcard.2008.11.019
17. Von Ruden SA, Murray MA, Grice JL, Proebstle AK, Kopacek KJ (2012) The pharmacotherapy implications of ventricular assist device in the patient with end-stage heart failure. J Pharm Pract 25(2):232-249. doi:10.1177/ 0897190011431635
18. Rossi M, Serraino GF, Jiritano F, Renzulli A (2012) What is the optimal anticoagulation in patients with a left ventricular assist device? Interact Cardiovasc Thorac Surg. doi:10.1093/icvts/ivs297
19. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329):71-86
20. Armstrong PC, Truss NJ, Ali FY, Dhanji AA, Vojnovic I, Zain ZN, Bishop-Bailey D, Paul-Clark MJ, Tucker AT, Mitchell JA, Warner TD (2008) Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2. J Thromb Haemost 6(11):1933-1943
21. Szczeklik A, Krzanowski M, Gora P, Radwan J (1992) Antiplatelet drugs and generation of thrombin in clotting blood. Blood 80(8):2006-2011
22. Massel D, Little SH (2001) Risks and benefits of adding antiplatelet therapy to warfarin among patients with prosthetic heart valves: a meta-analysis. J Am Coll Cardiol 37(2):569-578
23. Houel R, Mazoyer E, Boval B, Kirsch M, Vermes E, Drouet L, Loisance DY (2004) Platelet activation and aggregation profile in prolonged external ventricular support. J Thorac Cardiovasc Surg 128(2):197-202. doi:10.1016/j.jtcvs.2003.11.059 (Pubitemid 38969800)
24. Boyle AJ, Russell SD, Teuteberg JJ, Slaughter MS, Moazami N, Pagani FD, Frazier OH, Heatley G, Farrar DJ, John R (2009) Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. J Heart Lung Transplant 28(9):881-887. doi:10.1016/j.healun.2009.05.018
25. Miller LW, Pagani FD, Russell SD, John R, Boyle AJ, Aaronson KD, Conte JV, Naka Y, Mancini D, Delgado RM, MacGillivray TE, Farrar DJ, Frazier OH (2007) Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 357(9):885-896. doi:10.1056/NEJMoa067758 (Pubitemid 47347322)
26. Goldstein DJ (2003) Worldwide experience with the MicroMed DeBakey Ventricular Assist Device as a bridge to transplantation. Circulation 108(Suppl 1):II272-II277. doi:10.1161/01.cir.0000087387.02218.7e
27. Goldstein DJ, Zucker M, Arroyo L, Baran D, McCarthy PM, Loebe M, Noon GP (2005) Safety and feasibility trial of the MicroMed DeBakey ventricular assist device as a bridge to transplantation. J Am Coll Cardiol 45(6):962-963. doi:10.1016/j.jacc.2004.12.020 (Pubitemid 40342827)
28. Nakamura T, Uchiyama S, Yamazaki M, Iwata M (2002) Effects of dipyridamole and aspirin on shear-induced platelet aggregation in whole blood and platelet-rich plasma. Cerebrovasc Dis 14(3-4):234-238 (Pubitemid 36151424)
29. Yamamoto J, Taka T, Nakajima S, Ueda M, Sugimoto E, Sasaki Y, Muraki T, Seki J, Watanabe S (1999) A shear-induced in vitro platelet function test can assess clinically relevant anti-thrombotic effects. Platelets 10(2-3):178-184. doi:10.1080/09537109976266 (Pubitemid 29182288)
30. Tschopp M, Reinhart WH (2008) Platelet aggregation under high shear conditions during and after a 28-day administration of 100 mg acetylsalicylic acid in healthy volunteers. Clin Hemorheol Microcirc 38(1):45-50 (Pubitemid 350256700)
31. Turner NA, Moake JL, Kamat SG, Schafer AI, Kleiman NS, Jordan R, McIntire LV (1995) Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa. Circulation 91(5):1354-1362
32. Jesty J, Bluestein D (1999) Acetylated prothrombin as a substrate in the measurement of the procoagulant activity of platelets: elimination of the feedback activation of platelets by thrombin. Anal Biochem 272(1):64-70 (Pubitemid 29343383)
33. Claiborne TE, Girdhar G, Gallocher-Lowe S, Sheriff J, Kato YP, Pinchuk L, Schoephoerster RT, Jesty J, Bluestein D (2011) Thrombogenic potential of Innovia polymer valves versus Carpentier-Edwards Perimount Magna aortic bioprosthetic valves. ASAIO J 57(1):26-31. doi:10.1097/MAT.0b013e3181fcbd86
34. Girdhar G, Xenos M, Alemu Y, Chiu WC, Lynch BE, Jesty J, Einav S, Slepian MJ, Bluestein D (2012) Device thrombogenicity emulation: a novel method for optimizing mechanical circulatory support device thromboresistance. PLoS One 7(3):e32463. doi:10.1371/journal.pone.0032463
35. Slepian MJ, Alemu Y, Soares JS, Smith RG, Einav S, Bluestein D (2013) The Syncardia(™) total artificial heart: in vivo, in vitro, and computational modeling studies. J Biomech 46(2):266-275. doi:10.1016/j.jbiomech.2012.11.032
36. Schulz-Heik K, Ramachandran J, Bluestein D, Jesty J (2005) The extent of platelet activation under shear depends on platelet count: differential expression of anionic phospholipid and factor Va. Pathophysiol Haemost Thromb 34(6):255-262 (Pubitemid 43882423)
37. Jesty J, Yin W, Perrotta P, Bluestein D (2003) Platelet activation in a circulating flow loop: combined effects of shear stress and exposure time. Platelets 14(3):143-149 (Pubitemid 36609806)
38. Buerke M, Pittroff W, Meyer J, Darius H (1995) Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses. Am Heart J 130(3 Pt 1):465-472
39. Houel R, Mazoyer E, Kirsch M, Boval B, Drouet L, Loisance DY (2003) Resistance to aspirin after external ventricular assist device implantation. J Thorac Cardiovasc Surg 126(5):1636-1637. doi:10.1016/S0022 (Pubitemid 37449199)
40. Zimmermann N, Kienzle P, Weber AA, Winter J, Gams E, Schror K, Hohlfeld T (2001) Aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 121(5):982-984. doi:10.1067/mtc.2001.111416
41. Guthikonda S, Lev EI, Patel R, DeLao T, Bergeron AL, Dong JF, Kleiman NS (2007) Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 5(3):490-496. doi:10.1111/j.1538-7836.2007.02387.x (Pubitemid 46680680)
42. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S (2002) Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105(14):1650-1655 (Pubitemid 34298607)
43. Boeer K, Reinhofer M, Losche W (2010) Validation of a procedure to assess ASA-response in patients with decreased, initial TRAP induced aggregation. Platelets 21(5):314-319. doi:10.3109/09537101003763442
44. Rajah SM, Penny AF, Crow MJ, Pepper MD, Watson DA (1979) The interaction of varying doses of dipyridamole and acetyl salicylic acid on the inhibition of platelet functions and their effect on bleeding time. Br J Clin Pharmacol 8(5):483-489 (Pubitemid 10194834)
45. Eisert WG (2012) Dipyridamole in antithrombotic treatment. Adv Cardiol 47:78-86. doi:10.1159/000338053
46. Bluestein D, Einav S, Slepian MJ (2013) Device thrombogenicity emulation: a novel methodology for optimizing the thromboresistance of cardiovascular devices. J Biomech 46(2):338-344. doi:10.1016/j.jbiomech.2012.11.033
47. Michelson AD (1996) Flow cytometry: a clinical test of platelet function. Blood 87(12):4925-4936
48. Loffler C, Straub A, Bassler N, Pernice K, Beyersdorf F, Bode C, Siegenthaler MP, Peter K (2009) Evaluation of platelet activation in patients supported by the Jarvik 2000* high-rotational speed impeller ventricular assist device. J Thorac Cardiovasc Surg 137(3):736-741. doi:10.1016/j.jtcvs. 2008.09.019
49. Sheriff J, Bluestein D, Girdhar G, Jesty J (2010) High-shear stress sensitizes platelets to subsequent low-shear conditions. Ann Biomed Eng 38(4):1442-1450. doi:10.1007/s10439-010-9936-2
50. Lietz K (2010) Destination therapy: patient selection and current outcomes. J Card Surg 25(4):462-471. doi:10.1111/j.1540-8191.2010.01050.x
51. Lietz K, Miller LW (2008) Destination therapy: current results and future promise. Semin Thorac Cardiovasc Surg 20(3):225-233. doi:10.1053/j.semtcvs. 2008.08.004
52. Kurien S, Hughes KA (2012) Anticoagulation and bleeding in patients with ventricular assist devices: walking the tightrope. AACN Adv Crit Care 23(1):91-98. doi:10.1097/NCI.0b013e31824124d0
53. Xenos M, Girdhar G, Alemu Y, Jesty J, Slepian M, Einav S, Bluestein D (2010) Device Thrombogenicity Emulator (DTE) - design optimization methodology for cardiovascular devices: a study in two bileafletMHVdesigns. J Biomech 43(12):2400-2409. doi:10.1016/j.jbiomech.2010.04.020 Bioengineering